Get started
Author

Hubert Curcio

Observed names: Curcio, Hubert, H. Curcio
ORCID: 0000-0003-3428-506X
Observed ORCID: 0000-0003-3428-506X
OpenAlex ID: A5064696120
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
2023 · J. Remon, B. Besse, et al. · Annals of Oncology · 79
PDF
PFMG2025–integrating genomic medicine into the national healthcare system in France
2025 · Caroline Abadie, Aldja Abderrahmane, et al. · The Lancet Regional Health - Europe · 57
PDF
Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives
2022 · Mathieu Césaire, Juliette Montanari, et al. · Cancers · 48
PDF
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
2024 · Jordi Remon, Benjamin Besse, et al. · Journal of Clinical Oncology · 32
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma
2022 · Marco Tagliamento, Paolo Bironzo, et al. · Critical Reviews in Oncology/Hematology · 27
ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.
2024 · David Planchard, Nathalie Cozic, et al. · Journal of Clinical Oncology · 25
PDF
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
2023 · E. Pons-Tostivint, P. Hulo, et al. · Cancer Immunology Immunotherapy · 23
PDF
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study
2023 · Maud Velev, Cécile Dalban, et al. · European Journal of Cancer · 17
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer
2024 · Aurélie Swalduz, Camille Schiffler, et al. · Journal of Thoracic Oncology · 15
PDF
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.
2023 · Aurélie Swalduz, Hubert Curcio, et al. · Journal of Clinical Oncology · 14
Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study
2026 · David Planchard, Nathalie Cozic, et al. · Cancer Cell · 11
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)
2023 · Alain Vergnenegre, Isabelle Monnet, et al. · Lung Cancer · 9
Resected EGFR -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)
2024 · Jean-Bernard Auliac, Pascal-Alexandre Thomas, et al. · Therapeutic Advances in Medical Oncology · 6
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer
2024 · Camille Mehlman, Aurelie Swalduz, et al. · The Oncologist · 5
PDF
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort
2024 · Simon Nannini, Florian Guisier, et al. · Current Oncology · 5
PDF
Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)
2023 · Chantal Decroisette, Laurent Greillier, et al. · Journal of Immunotherapy · 5
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study
2023 · Hélène Babey, Philippe Jamme, et al. · Targeted Oncology · 5
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis
2025 · Antoine Bronstein, Hubert Curcio, et al. · Clinical Lung Cancer · 4
The impact of introducing deep learning based [18F]FDG PET denoising on EORTC and PERCIST therapeutic response assessments in digital PET/CT
2024 · Kathleen Weyts, Justine Lequesne, et al. · EJNMMI Research · 4
PDF
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study
2025 · Thomas Pierret, Laurent Greillier, et al. · Lung Cancer · 3
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study
2024 · Marion Ferreira, Aurélie Swalduz, et al. · Lung Cancer · 3
Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France
2024 · Mateo Sanchis-Borja, Florian Guisier, et al. · OncoTargets and Therapy · 3
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
2023 · Hélène Doubre, Laurent Greillier, et al. · Journal of Cancer Research and Clinical Oncology · 3
PDF
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
2023 · E. Pons-Tostivint, P. Hulo, et al. · Cancer Immunology Immunotherapy · 3
PDF
Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
2025 · Geoffrey Liu, Shi Feng Nyaw, et al. · Cancer Medicine · 2
PDF
Works count: 66
Citation count: 424
H-index: 11
I10-index: 11
Year
Topic
Type